Moderna, Inc. - Common Stock (MRNA)

74.46
-5.31 (-6.66%)
NASDAQ· Last Trade: Jul 8th, 12:28 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close79.77
Open77.34
Bid74.46
Ask74.51
Day's Range73.74 - 78.30
52 Week Range22.28 - 85.60
Volume3,409,586
Market Cap29.34B
PE Ratio (TTM)-10.24
EPS (TTM)-7.3
Dividend & YieldN/A (N/A)
1 Month Average Volume9,892,191

Chart

About Moderna, Inc. - Common Stock (MRNA)

Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases. Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally. Read More

News & Press Releases

Gapping S&P500 stocks in Wednesday's sessionchartmill.com
Via Chartmill · July 8, 2026
Wednesday's pre-market session: top gainers and losers in the S&P500 indexchartmill.com
Via Chartmill · July 8, 2026
Moderna Appoints Michael McDonnell to Board of Directors
Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience
By Moderna, Inc. · Via ACCESS Newswire · July 8, 2026
Moderna Stock Is Soaring. Is It Too Late to Buy?fool.com
Moderna's growth story is just beginning.
Via The Motley Fool · July 7, 2026
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even Morefool.com
These stocks have jumped in the double- and triple-digits.
Via The Motley Fool · July 6, 2026
Stay informed with the top movers within the S&P500 index on Monday.chartmill.com
Via Chartmill · July 6, 2026
Monday's pre-market session: top gainers and losers in the S&P500 indexchartmill.com
Via Chartmill · July 6, 2026
Wall Street Got the Weak Jobs Report It Wanted. Chip Stocks Wrecked the Rally Anyway.chartmill.com
Via Chartmill · July 6, 2026
MarketBeat Week in Review – 06/29 - 07/03marketbeat.com
MarketBeat's weekly roundup covers a weaker June jobs report, tech sector rotation, and top analyst picks including TSLA, AVGO, PLTR, MRNA, and NEE heading into Q2 earnings season.
Via MarketBeat · July 4, 2026
Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%. What Gives?fool.com
When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.
Via The Motley Fool · July 3, 2026
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?fool.com
Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.
Via The Motley Fool · July 3, 2026
3 Cash-Heavy Stocks with Warning Signs
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...
Via StockStory · July 3, 2026
Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its pe...
Via StockStory · July 2, 2026
Thursday's session: top gainers and losers in the S&P500 indexchartmill.com
Via Chartmill · July 2, 2026
These S&P500 stocks are moving in today's sessionchartmill.com
Via Chartmill · July 2, 2026
Short Squeeze Alert—Moderna Stock Surges on New Strategymarketbeat.com
Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines faces a multi-year path to revenue.
Via MarketBeat · July 1, 2026
Is Moderna Stock a No-Brainer Buy After a Key FDA Win?fool.com
Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.
Via The Motley Fool · June 30, 2026
Therapeutics Stocks Q1 Recap: Benchmarking Vertex Pharmaceuticals (NASDAQ:VRTX)
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers. ...
Via StockStory · June 29, 2026
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers. Over th...
Via StockStory · June 29, 2026
Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Sidechartmill.com
Via Chartmill · June 29, 2026
Discover which S&P500 stocks are making waves on Friday.chartmill.com
Via Chartmill · June 26, 2026
Friday's session: top gainers and losers in the S&P500 indexchartmill.com
Via Chartmill · June 26, 2026
This Stock Has Already Doubled This Year and Is Still Racing Towards a Major Catalystfool.com
It's not just a "pandemic stock," after all.
Via The Motley Fool · June 26, 2026
Moderna Science Day Highlights Expanding Potential of mRNA Platform
Provides broad overview of Company's research and early development programs expected to continue to fuel future growth
By Moderna, Inc. · Via ACCESS Newswire · June 25, 2026
Therapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via StockStory · June 24, 2026